| Bioactivity | αGalCer-RBD is a self-adjuvanting lipoprotein conjugate. αGalCer-RBD induces potent immunity against SARS-CoV-2 and its variants of concern. αGalCer-RBD conjugate induces RBD-specific, cytokine-producing T cell development. αGalCer-RBD has great potential to be an effective COVID-19 vaccine candidate. α-Galactosylceramide (αGalCer) is a potent invariant natural killer T cell (iNKT) agonist[1]. RBD: receptor-binding domain |
| Invitro | The first time conjugates the iNKT cell agonist on the protein antigen, and the resulting αGalCer-RBD conjugate anchored on liposomes biomimicking the virus capsid structure remarkably enhances the protective immune response against SARS-CoV-2[1]. |
| In Vivo | αGalCer-RBD enhances the immune efficacy of the adjuvant and produces significantly stronger humoral responses and cellular responses in mice[1]. |
| Name | αGalCer-RBD |
| Formula | C60H118N4O14 |
| Molar Mass | 1119.60 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wang J, et al. Self-Adjuvanting Lipoprotein Conjugate αGalCer-RBD Induces Potent Immunity against SARS-CoV-2 and its Variants of Concern. J Med Chem. 2022;65(3):2558-2570. |